These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31731988)

  • 21. The diagnosis of latent tuberculosis infection (LTBI): currently available tests, future developments, and perspectives to eliminate tuberculosis (TB).
    Zellweger JP; Sotgiu G; Corradi M; Durando P
    Med Lav; 2020 Jun; 111(3):170-183. PubMed ID: 32624559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New guidelines for latent tuberculosis.
    Mushtaq A
    Lancet Infect Dis; 2020 Apr; 20(4):414. PubMed ID: 32222207
    [No Abstract]   [Full Text] [Related]  

  • 23. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
    Campbell JR; Trajman A; Cook VJ; Johnston JC; Adjobimey M; Ruslami R; Eisenbeis L; Fregonese F; Valiquette C; Benedetti A; Menzies D
    Lancet Infect Dis; 2020 Mar; 20(3):318-329. PubMed ID: 31866327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis for Latent Tuberculosis Infection: New Alternatives.
    Carranza C; Pedraza-Sanchez S; de Oyarzabal-Mendez E; Torres M
    Front Immunol; 2020; 11():2006. PubMed ID: 33013856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global Epidemiology of Tuberculosis and Progress Toward Meeting Global Targets - Worldwide, 2018.
    MacNeil A; Glaziou P; Sismanidis C; Date A; Maloney S; Floyd K
    MMWR Morb Mortal Wkly Rep; 2020 Mar; 69(11):281-285. PubMed ID: 32191687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in the diagnosis and treatment of latent tuberculosis infection.
    Jung YEG; Schluger NW
    Curr Opin Infect Dis; 2020 Apr; 33(2):166-172. PubMed ID: 32022744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global trends and gaps in research related to latent tuberculosis infection.
    Chaw L; Chien LC; Wong J; Takahashi K; Koh D; Lin RT
    BMC Public Health; 2020 Mar; 20(1):352. PubMed ID: 32183753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Latent Tuberculosis Infection.
    Shah M; Dorman SE
    N Engl J Med; 2021 Dec; 385(24):2271-2280. PubMed ID: 34879450
    [No Abstract]   [Full Text] [Related]  

  • 29. Latent Tuberculosis Infection.
    Hook EB
    N Engl J Med; 2022 Mar; 386(13):e33. PubMed ID: 35353974
    [No Abstract]   [Full Text] [Related]  

  • 30. The knowns and unknowns of latent Mycobacterium tuberculosis infection.
    Boom WH; Schaible UE; Achkar JM
    J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33529162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Latent tuberculosis infection: approach and therapeutic schemes.
    Fortún J; Navas E
    Rev Esp Quimioter; 2022 Oct; 35 Suppl 3(Suppl 3):94-96. PubMed ID: 36285867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of Severe Adverse Events Reported Among Patients Receiving Isoniazid-Rifapentine Treatment for Latent Mycobacterium tuberculosis Infection-United States, 2012-2016.
    Schmit KM; Wortham JM; Ho CS; Powell KM
    Clin Infect Dis; 2020 Dec; 71(9):2502-2505. PubMed ID: 32185390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Latent tuberculosis infection: recent progress and challenges in South Korea.
    Jeon D
    Korean J Intern Med; 2020 Mar; 35(2):269-275. PubMed ID: 32131570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of latent tuberculosis infection in China: Exploring solutions suitable for high-burden countries.
    Cui X; Gao L; Cao B
    Int J Infect Dis; 2020 Mar; 92S():S37-S40. PubMed ID: 32114201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breaking barriers: The potential of nanosystems in antituberculosis therapy.
    Carnero Canales CS; Marquez Cazorla JI; Marquez Cazorla RM; Roque-Borda CA; Polinário G; Figueroa Banda RA; Sábio RM; Chorilli M; Santos HA; Pavan FR
    Bioact Mater; 2024 Sep; 39():106-134. PubMed ID: 38783925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The great imitator: Tuberculosis with lymphadenopathy and splenomegaly.
    Hall AD; Rodriguez LVM; Vearrier J; Patel K; Hambley BC; Huaman MA
    IDCases; 2024; 36():e01968. PubMed ID: 38646597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rising role of 3D-printing in delivery of therapeutics for infectious disease.
    Kyser AJ; Fotouh B; Mahmoud MY; Frieboes HB
    J Control Release; 2024 Feb; 366():349-365. PubMed ID: 38182058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in Diagnostics and Drug Discovery against Resistant and Latent Tuberculosis Infection.
    Shleider Carnero Canales C; Marquez Cazorla J; Furtado Torres AH; Monteiro Filardi ET; Di Filippo LD; Costa PI; Roque-Borda CA; Pavan FR
    Pharmaceutics; 2023 Sep; 15(10):. PubMed ID: 37896169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Latent Tuberculosis: Challenges in Diagnosis and Treatment, Perspectives, and the Crucial Role of Biomarkers.
    Palanivel J; Sounderrajan V; Thangam T; Rao SS; Harshavardhan S; Parthasarathy K
    Curr Microbiol; 2023 Oct; 80(12):392. PubMed ID: 37884822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Latent tuberculosis infection in the outpatient general medicine clinic: Efficacy of a nurse-run electronic directly observed treatment program.
    Levine S; Fraulino D; Krupka P; Velamakanni S
    Prev Med Rep; 2023 Oct; 35():102321. PubMed ID: 37519447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.